Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Quipt Home Medical Corp T.QIPT

Alternate Symbol(s):  QIPT

Quipt Home Medical Corp. is a home medical equipment provider. The Company specializes in improving the home management of chronic illness through the application of telehealth systems and automated distribution. It provides in-home monitoring and disease management services, including end-to-end respiratory solutions for patients in the United States. It offers nebulizers, oxygen concentrators, continuous positive airway pressure (CPAP) and Bilevel Positive Airway Pressure (BiPAP) units; traditional and non-traditional medical respiratory equipment and services, and non-invasive ventilation equipment, supplies, and services. The Company's product offerings include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. Its products and services consist of sleep apnea and pap treatment, home ventilation, daily and ambulatory aides, and respiratory equipment rental.


TSX:QIPT - Post by User

Post by Trademark11on Nov 15, 2021 6:03am
636 Views
Post# 34126020

What is the POTENTIAL REVENUE gain with the shelf in place?

What is the POTENTIAL REVENUE gain with the shelf in place?

Ammunition:
30MM Cash+20 MM LOC+200MM shelf = 250MM

Fact:
1.  Average price of acqusition targets over the last 3 years = 0.8x Rev
2.  200MM shelf at 6.05 = approx 33MM shares.Total share count would be 65MM 
3.  2022 Rev Runrate = 125MM 
4.  Above 350 MM Rev company forcasts EBITDA = 25%

If managment deploys all of their ammunition in 2022 (Doubtful):

At 0.8x Revenue 250MM can purchase approx 310 MM
2022 analyst concensus revenue =  125 MM
Total Potential Rev = 435MM
EBITDA @ 25% = 109 MM
109MM EBITDA / 65MM shares = $1.68sh

At Trading multiple of 6x = $10.06 =    67% upside
                                   8x = $13.40 =  123% upside
                                  10x = $16.80 = 180% upside
                                  12x = $20.10 =  235% upside


NOTE:  Deployment of all ammunition in one fiscal year is an unlikely POSSIBILITY NOT A PROBABILITY.  Anything above 70-80MM would be a horizontal merger of equals and done to attain economies of scale and need time for digestion. 

However, it is helpful to know the POTENTIAL revenue scale with the capital the company has to work with.  

(PS bashers, I am aware that there are variables here which you will porobably refute, but I have chosen what I feel to be reasonable values)

Do your own DD, heavily invested, active trader

<< Previous
Bullboard Posts
Next >>